13 Feb FibroBiologics
Hamid Khoja, Ph.D., Chief Scientific Officer
April 16 | 9:00am | Salone dei Cavalieri, Section 2
Houston Texas
(NASDAQ: FBLG)
FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. Our proprietary fibroblast platform serves as the Foundation for developing biologic cures and treatments for chronic diseases, including chronic wound healing, multiple sclerosis, degenerative disc disease, psoriasis, diabetes, cancer, and anti-aging extension of life applications such as thymic involution reversal. Currently, FibroBiologics holds 160+ U.S. and International issued/pending patents across a variety of clinical pathways, chronic wound healing, including multiple sclerosis, cartilage repair, degenerative disc, cancer, psoriasis, cancer, diabetes, lupus, and extension of life programs.
